JP2012517965A5 - - Google Patents

Download PDF

Info

Publication number
JP2012517965A5
JP2012517965A5 JP2011549472A JP2011549472A JP2012517965A5 JP 2012517965 A5 JP2012517965 A5 JP 2012517965A5 JP 2011549472 A JP2011549472 A JP 2011549472A JP 2011549472 A JP2011549472 A JP 2011549472A JP 2012517965 A5 JP2012517965 A5 JP 2012517965A5
Authority
JP
Japan
Prior art keywords
formula
reaction
above meanings
compound
dmf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011549472A
Other languages
English (en)
Other versions
JP5667085B2 (ja
JP2012517965A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/000717 external-priority patent/WO2010091824A1/en
Publication of JP2012517965A publication Critical patent/JP2012517965A/ja
Publication of JP2012517965A5 publication Critical patent/JP2012517965A5/ja
Application granted granted Critical
Publication of JP5667085B2 publication Critical patent/JP5667085B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

上記反応順序とは異なって、式（I）（式中、B、R4、R7、ｍ、ｎ及びR10は上記意味を有し、そしてR6は水素又は１−４C−アルキルである）の化合物は、式（III a）（式中、Xは適切な脱離基、例えばハロゲン原子又はスルホネートである）の対応する化合物と、式（II）（式中、R7、ｍ及びｎは上記意味を有する）のピペリジン誘導体との反応により得られる。反応は好ましくは、塩基、例えばトリエチルアミンの存在下で、60〜100℃の温度で、不活性溶媒、例えばDMF下で実施される。
JP2011549472A 2009-02-13 2010-02-05 Ａｋｔインヒビターとしての融合されたピリミジン Expired - Fee Related JP5667085B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09152805.9 2009-02-13
EP09152805 2009-02-13
PCT/EP2010/000717 WO2010091824A1 (en) 2009-02-13 2010-02-05 Fused pyrimidines as akt inhibitors

Publications (3)

Publication Number Publication Date
JP2012517965A JP2012517965A (ja) 2012-08-09
JP2012517965A5 true JP2012517965A5 (ja) 2014-09-04
JP5667085B2 JP5667085B2 (ja) 2015-02-12

Family

ID=42019301

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011549472A Expired - Fee Related JP5667085B2 (ja) 2009-02-13 2010-02-05 Ａｋｔインヒビターとしての融合されたピリミジン

Country Status (8)

Country Link
US (1) US20130310362A1 (ja)
EP (1) EP2396331B1 (ja)
JP (1) JP5667085B2 (ja)
CN (1) CN102361872B (ja)
CA (1) CA2752114C (ja)
ES (1) ES2435804T3 (ja)
HK (1) HK1166984A1 (ja)
WO (1) WO2010091824A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948447B1 (en) * 2013-01-23 2016-09-21 Astrazeneca AB Chemical compounds
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
CN106164066B (zh) 2014-02-13 2020-01-17 因赛特公司 作为lsd1抑制剂的环丙胺
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP2907811A1 (en) 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
ES2757948T3 (es) 2015-04-03 2020-04-30 Incyte Corp Compuestos heterocíclicos como inhibidores LSD1
CR20180152A (es) 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089434A2 (en) * 2002-04-19 2003-10-30 Cellular Genomics, Inc. IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF
US7579355B2 (en) * 2003-04-24 2009-08-25 Merck & Co., Inc. Inhibitors of Akt activity
CA2561311A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2008524339A (ja) 2004-12-15 2008-07-10 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性のインヒビター
US7589068B2 (en) 2005-02-14 2009-09-15 Merck & Co., Inc. Inhibitors of Akt activity
EP1898903B8 (en) 2005-06-10 2013-05-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
BRPI0815207A2 (pt) * 2007-08-14 2017-03-28 Bayer Schering Pharma Ag pirimidinas bicíclicas fundidas
EP2176259B1 (en) * 2007-08-14 2011-03-30 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment

Similar Documents

Publication Publication Date Title
JP2012517965A5 (ja)
JP2007523139A5 (ja)
DK1678119T3 (da) Fremgangsmåde til fremstilling af 2-dihalogenacyl-3-amino-acrylsyreestere og 3-dihalogenmethyl-pyrazol-4-carboxylsyreestere
JP2013010731A5 (ja) 複素環化合物
JP2014516210A5 (ja)
JP2007518723A5 (ja)
JP2009523146A5 (ja)
JP2015524409A5 (ja)
JP2009120624A5 (ja)
JP2009135422A5 (ja)
JP2015042636A5 (ja) 有機化合物
JP2013147496A5 (ja) 有機金属錯体
EA201201033A1 (ru) Циклический амин и акарицид
JP2015063518A5 (ja) 有機化合物
JP2009539912A5 (ja)
EA201290401A1 (ru) Азотсодержащее гетероциклическое соединение и сельскохозяйственный фунгицид
JP2013010749A5 (ja) カルバゾール化合物
JP2009539914A5 (ja)
EA201070872A1 (ru) Производные азабициклических карбоксамидов, их получение и их применение в терапии
JP2013010730A5 (ja) フルオレン化合物および有機化合物
JP2013028597A5 (ja)
CY1108792T1 (el) Παραγωγα διοξανιου-2-αλκυλκαρβαμικου, η παρασκευη τους και η εφαρμογη τους στην θεραπευτικη αγωγη
JP2007514047A5 (ja)
JP2014519537A5 (ja)
JP2014148663A5 (ja)